Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

International Journal of Infectious Diseases

Volumn 59, Issue , 2017, Pages 118-123

  Castón, Juan J ^a   Lacort Peralta, Isabel ^a   Martín Dávila, Pilar ^b   Loeches, Belén ^c   Tabares, Salvador ^a   Temkin, Liz ^d   Torre Cisneros, Julián ^a   Paño Pardo, José R ^c,e  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Bloodstream infections; Carbapenemase producing Enterobacteriaceae; Ceftazidime avibactam

Indexed keywords

AMINOGLYCOSIDE; AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEM DERIVATIVE; COLISTIN; FOSFOMYCIN; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; CEFTAZIDIME;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY FAILURE; MALE; MIDDLE AGED; MORTALITY RATE; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SEPTIC SHOCK; TREATMENT OUTCOME; BACTEREMIA; BIOSYNTHESIS; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; HEMATOLOGIC DISEASE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; COHORT STUDIES; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85019587923     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2017.03.021     Document Type: Article

References (20)

1. Acycaz (Ceftazidime-avibactam), Prescribing information. 2016, Forest Pharmaceuticals, Inc., Cincinnati, Ohio.
2. Center for Disease Control and Prevention - Healthcare-associated Infections (HAIs): CRE Definition. https://www.cdc.gov/hai/organisms/cre/definition.html.
3. de Jonge, B.L.M., Karlowsky, J.A., Kazmierczak, K.M., Biedenbachb, D.J., Sahmb, D.F., Nichols, W.W., In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012-2014). Antimicrob Agents Chemother 60 (2016), 3163–3169.
4. Freifeld, A.G., Bow, E.J., Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52 (2011), 427–431.
5. Hackel, M., Kazmierczak, K.M., Hoban, D.J., Biedenbach, D.J., Bouchillon, S.K., de Jonge, B.L., Assesment of the in vitro activity of ceftazidime-avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM global surveillance study, 2012 to 2014. Antimicrob Agents Chemother 60 (2016), 4677–4683.
6. Hirsch, E.B., Tam, V.H., Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65 (2010), 1119–1125.
7. Horan, T.C., Andrus, M., Dudeck, M.A., CDC/NHSN surveillance definition of health care-infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36 (2008), 309–332.
8. Maio Carrilho, C.M., de Oliveira, L.M., Gaudereto, J., A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BM Infect Dis 16 (2016), 629–638.
9. Neuner, E.A., Yeh, J.Y., Hall, G.S., Sekeres, J., Endimiani, A., Bonomo, R.A., Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 69 (2011), 357–362.
10. Paño, J.R., Serrano, S., Ramos, J.C., Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features and prognosis. Enferm Infecc Microbiol Clin 32:Suppl 4 (2014), 41–48.
11. Qureshi, Z.A., Paterson, D.L., Potoski, B.A., Sekeres, J., Endimiani, A., Bonomo, R.A., Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56 (2012), 2108–2113.
12. Rodríguez-Baño, J., Cisneros, J.M., Cobos-Trigueros, N., Fresco, G., Navarro-San Francisco, C., Gudiol, C., Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin 33:337 (2015), e1–e21.
13. Satlin, M.J., Cohen, N., Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. Journal of Infection 73 (2016), 336–345.
14. Satlin, M.J., Calfee, D.P., Chen, L., Fauntleroy, K.A., Wilson, S.J., Jenkins, S.G., Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 54 (2013), 799–806.
15. Shields, R.K., Clancy, C.J., Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases and porin mutations on the vitro activity of ceftazidime-avibactam against carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 59 (2015), 5793–5797.
16. Souli, M., Galani, I., Antoniadou, A., Papadomichelakis, E., Poulakou, G., Panagea, T., An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 50 (2010), 364–373.
17. Spellberg, B., Bonomo, R.A., Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: “Wére Gonna Need a Bigger Boat”. Clin Infect Dis, 2016 Epub ahead of print.
18. Tofas, P., Skiada, A., Angelopoulou, M., Sipsas, N., Pavlopoulou, I., Tsaousi, S., Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. Int J Antimicrob Agents 47:4 (2016), 335–339.
19. Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E.M., Tumietto, F., Marchese, A., Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55 (2012), 943–950.
20. Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., Pitiriga, V., Ranellou, K., Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17 (2011), 1798–1803.